These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 6537120)

  • 1. [Changes in peripheral blood monocyte number in patients with multiple myeloma treated with melphalan].
    Mendek-Czajkowska E; Rostkowska J; Mariańska B; Sawicki Z; Maj S
    Acta Haematol Pol; 1984; 15(3-4):119-24. PubMed ID: 6537120
    [No Abstract]   [Full Text] [Related]  

  • 2. [Myeloma, melphalan and acute myelo-monocytic leukemia. Apropos of a case].
    Cywiner-Golenzer C; Adotti F; Marsan C; Quillard A; Henon P; Grimaldi A; Dryll A
    Sem Hop; 1974 Jan; 50(3):207-11. PubMed ID: 4367926
    [No Abstract]   [Full Text] [Related]  

  • 3. [Myelofibrosis following a hyposecreting myeloma treated by vincristine, melphalan].
    Schneider M; Cassuto JP; Duplay H; Viguier E; Lesbats G
    Nouv Presse Med; 1979 Sep; 8(35):2831-2. PubMed ID: 503814
    [No Abstract]   [Full Text] [Related]  

  • 4. Evolution of multiple myeloma treatment from melphalan monotherapy to bone marrow transplantation.
    Hájek R; Adam Z; Vásová I; Král Z
    Acta Med Austriaca; 1996; 23(3):85-91. PubMed ID: 8798281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral melphalan at diagnosis hampers adequate collection of peripheral blood progenitor cells in multiple myeloma.
    Boccadoro M; Palumbo A; Bringhen S; Merletti F; Ciccone G; Richiardi L; Rus C; Bertola A; Giaccone L; Omedè P; Musto P
    Haematologica; 2002 Aug; 87(8):846-50. PubMed ID: 12161361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preferential in vivo DNA repair of melphalan-induced damage in human genes is greatly affected by the local chromatin structure.
    Souliotis VL; Dimopoulos MA; Episkopou HG; Kyrtopoulos SA; Sfikakis PP
    DNA Repair (Amst); 2006 Aug; 5(8):972-85. PubMed ID: 16781199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Case of IgG-K myeloma successfully treated with melphalan but terminating in acute myelogenous leukemia 2 years and 8 months later].
    Saitoh A; Tsushima T; Narita K; Fujiwara S; Kawamura S; Chiba Y; Yoshida Y
    Rinsho Ketsueki; 1982 Jun; 23(6):862-9. PubMed ID: 6960198
    [No Abstract]   [Full Text] [Related]  

  • 8. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.
    Hulin C; Facon T; Rodon P; Pegourie B; Benboubker L; Doyen C; Dib M; Guillerm G; Salles B; Eschard JP; Lenain P; Casassus P; Azaïs I; Decaux O; Garderet L; Mathiot C; Fontan J; Lafon I; Virion JM; Moreau P
    J Clin Oncol; 2009 Aug; 27(22):3664-70. PubMed ID: 19451428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment of multiple myeloma with melphalan: 35 personal cases].
    Dryll A; Ryckewaert A; Kahn MF; Hayat M; de Seze S
    Sem Hop; 1970 Jan; 46(5):289-98. PubMed ID: 4327260
    [No Abstract]   [Full Text] [Related]  

  • 10. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression.
    Mateos MV; Hernández JM; Hernández MT; Gutiérrez NC; Palomera L; Fuertes M; Garcia-Sanchez P; Lahuerta JJ; de la Rubia J; Terol MJ; Sureda A; Bargay J; Ribas P; Alegre A; de Arriba F; Oriol A; Carrera D; García-Laraña J; García-Sanz R; Bladé J; Prósper F; Mateo G; Esseltine DL; van de Velde H; San Miguel JF
    Haematologica; 2008 Apr; 93(4):560-5. PubMed ID: 18322252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Letter: Myeloma and myelo-monocytic leukemia. Role of melphalan].
    Marsan C; Henon P; Quillard A; Grimaldi A; Cywiner-Golener C
    Nouv Presse Med; 1973 Dec; 2(44):2958. PubMed ID: 4521337
    [No Abstract]   [Full Text] [Related]  

  • 12. [Myeloma with hypereosinophilia. Eosinophil reaction following melphalan].
    Ozgüven O; Sebik F; Basci A
    Presse Med; 1983 Mar; 12(11):704. PubMed ID: 6220307
    [No Abstract]   [Full Text] [Related]  

  • 13. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479.
    Oken MM; Harrington DP; Abramson N; Kyle RA; Knospe W; Glick JH
    Cancer; 1997 Apr; 79(8):1561-7. PubMed ID: 9118039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deletion of 5q31 and 7q31 in patients with stable melphalan treated multiple myeloma.
    Amiel A; Yukla M; Yogev S; Manor Y; Fejgin MD; Lishner M
    Cancer Genet Cytogenet; 2004 Jul; 152(1):84-7. PubMed ID: 15193449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Dysmyelopoietic syndrome 7 years after melphalan treatment of multiple myeloma. Clinical case].
    Scolozzi R; Boccafogli A
    Minerva Med; 1983 Jul; 74(28-29):1783-5. PubMed ID: 6866310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intermediate-dose (25mg/m2) IV melphalan for multiple myeloma with renal failure.
    Vigneau C; Ardiet C; Bret M; Laville M; Fiere D; Tranchand B; Fouque D
    J Nephrol; 2002; 15(6):684-9. PubMed ID: 12495285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alkeran and multiple myeloma.
    Med Lett Drugs Ther; 1966 Apr; 8(8):32. PubMed ID: 5913764
    [No Abstract]   [Full Text] [Related]  

  • 18. Cryotherapy for the prevention of high-dose melphalan-induced oral mucositis.
    Mori T; Aisa Y; Yamazaki R; Mihara A; Ikeda Y; Okamoto S
    Bone Marrow Transplant; 2006 Nov; 38(9):637-8. PubMed ID: 16953203
    [No Abstract]   [Full Text] [Related]  

  • 19. Melphalan 220 mg/m2 followed by peripheral blood stem cell transplantation in 27 patients with advanced multiple myeloma.
    Moreau P; Milpied N; Mahé B; Juge-Morineau N; Rapp MJ; Bataille R; Harousseau JL
    Bone Marrow Transplant; 1999 May; 23(10):1003-6. PubMed ID: 10373065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Acute hemolysis caused by glucose-6-phosphate dehydrogenase deficiency at the outset of myeloma therapy. Role of melphalan?].
    Casassus P; Vannetzel JM; Lortholary P
    Nouv Presse Med; 1982 Jun; 11(30):2296. PubMed ID: 7110993
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.